Limits...
Estrogenicity of glabridin in Ishikawa cells.

Su Wei Poh M, Voon Chen Yong P, Viseswaran N, Chia YY - PLoS ONE (2015)

Bottom Line: Past studies have shown that glabridin resulted in favorable outcome similar to 17β-estradiol (17β-E2), suggesting a possible role as an estrogen replacement therapy (ERT).However, glabridin also induced an increase in cell proliferation.When glabridin was treated together with 17β-E2, synergistic estrogenic effect was observed with a slight decrease in cell proliferation as compared to treatment by 17β-E2 alone.

View Article: PubMed Central - PubMed

Affiliation: School of Biosciences, Division of Medicine, Pharmacy and Health Sciences, Taylor's University, No. 1, Jln Taylor's, 47500 Subang Jaya, Malaysia.

ABSTRACT
Glabridin is an isoflavan from licorice root, which is a common component of herbal remedies used for treatment of menopausal symptoms. Past studies have shown that glabridin resulted in favorable outcome similar to 17β-estradiol (17β-E2), suggesting a possible role as an estrogen replacement therapy (ERT). This study aims to evaluate the estrogenic effect of glabridin in an in-vitro endometrial cell line -Ishikawa cells via alkaline phosphatase (ALP) assay and ER-α-SRC-1-co-activator assay. Its effect on cell proliferation was also evaluated using Thiazoyl blue tetrazolium bromide (MTT) assay. The results showed that glabridin activated the ER-α-SRC-1-co-activator complex and displayed a dose-dependent increase in estrogenic activity supporting its use as an ERT. However, glabridin also induced an increase in cell proliferation. When glabridin was treated together with 17β-E2, synergistic estrogenic effect was observed with a slight decrease in cell proliferation as compared to treatment by 17β-E2 alone. This suggest that the combination might be better suited for providing high estrogenic effects with lower incidences of endometrial cancer that is associated with 17β-E2.

No MeSH data available.


Related in: MedlinePlus

Effect of varying concentrations of glabridin in comparison to 1nM 17β-E2.The values represent the mean activity of three treatment group. *P<0.05 and ** P≤0.01 against the untreated control.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4376725&req=5

pone.0121382.g005: Effect of varying concentrations of glabridin in comparison to 1nM 17β-E2.The values represent the mean activity of three treatment group. *P<0.05 and ** P≤0.01 against the untreated control.

Mentions: Based on the MTT assay, glabridin also induced a dose-dependent increase in cell proliferation from 1nM to 10μM, similar to that of 17β-E2 [16], though not as high as 10nM 17β-E2 (Fig. 5). This increase in cell proliferation was also observed in other phytoestrogens such as genistein [28]. For glabridin, the maximum induction of cell proliferation corresponds to the highest ALP induction concentration of 10μM glabridin (22.37% increase from control). This suggests that ALP activity and cell viability in Ishikawa cells induced by glabridin are closely associated, whereby an increase in ALP activity seems to be followed by an increase in cell proliferation.


Estrogenicity of glabridin in Ishikawa cells.

Su Wei Poh M, Voon Chen Yong P, Viseswaran N, Chia YY - PLoS ONE (2015)

Effect of varying concentrations of glabridin in comparison to 1nM 17β-E2.The values represent the mean activity of three treatment group. *P<0.05 and ** P≤0.01 against the untreated control.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4376725&req=5

pone.0121382.g005: Effect of varying concentrations of glabridin in comparison to 1nM 17β-E2.The values represent the mean activity of three treatment group. *P<0.05 and ** P≤0.01 against the untreated control.
Mentions: Based on the MTT assay, glabridin also induced a dose-dependent increase in cell proliferation from 1nM to 10μM, similar to that of 17β-E2 [16], though not as high as 10nM 17β-E2 (Fig. 5). This increase in cell proliferation was also observed in other phytoestrogens such as genistein [28]. For glabridin, the maximum induction of cell proliferation corresponds to the highest ALP induction concentration of 10μM glabridin (22.37% increase from control). This suggests that ALP activity and cell viability in Ishikawa cells induced by glabridin are closely associated, whereby an increase in ALP activity seems to be followed by an increase in cell proliferation.

Bottom Line: Past studies have shown that glabridin resulted in favorable outcome similar to 17β-estradiol (17β-E2), suggesting a possible role as an estrogen replacement therapy (ERT).However, glabridin also induced an increase in cell proliferation.When glabridin was treated together with 17β-E2, synergistic estrogenic effect was observed with a slight decrease in cell proliferation as compared to treatment by 17β-E2 alone.

View Article: PubMed Central - PubMed

Affiliation: School of Biosciences, Division of Medicine, Pharmacy and Health Sciences, Taylor's University, No. 1, Jln Taylor's, 47500 Subang Jaya, Malaysia.

ABSTRACT
Glabridin is an isoflavan from licorice root, which is a common component of herbal remedies used for treatment of menopausal symptoms. Past studies have shown that glabridin resulted in favorable outcome similar to 17β-estradiol (17β-E2), suggesting a possible role as an estrogen replacement therapy (ERT). This study aims to evaluate the estrogenic effect of glabridin in an in-vitro endometrial cell line -Ishikawa cells via alkaline phosphatase (ALP) assay and ER-α-SRC-1-co-activator assay. Its effect on cell proliferation was also evaluated using Thiazoyl blue tetrazolium bromide (MTT) assay. The results showed that glabridin activated the ER-α-SRC-1-co-activator complex and displayed a dose-dependent increase in estrogenic activity supporting its use as an ERT. However, glabridin also induced an increase in cell proliferation. When glabridin was treated together with 17β-E2, synergistic estrogenic effect was observed with a slight decrease in cell proliferation as compared to treatment by 17β-E2 alone. This suggest that the combination might be better suited for providing high estrogenic effects with lower incidences of endometrial cancer that is associated with 17β-E2.

No MeSH data available.


Related in: MedlinePlus